Harrow Q2 revenue $63.7M (+30% YoY); net income $5M; VEVYE on track for >$100M; adds Samsung Bioepis

HARROW, INC.

2025-Q2 EPS reported -$0.35 vs consensus $0.01 ▼ miss (-4829.7%)

Total revenues $63.7M, up 30% YoY; GAAP net income $5.0M vs loss of $6.5M; Adj EBITDA $17.0M (up from $8.8M).
VEVYE dry eye revenue on track to exceed $100M in 2025; Q2 market share 7.8%; 66% sequential prescription growth.
IHEEZO revenue $18.3M (+62% YoY, +251% QoQ); TRIESENCE added 870 new accounts YTD; unit growth 32% QoQ.
Secured exclusive U.S. rights to Samsung Bioepis ophthalmic biosimilars (BYOOVIZ, OPUVIZ) in July 2025.
Acquired U.S. rights for BYQLOVI (clobetasol) in June 2025; Apollo Care alliance to expand VEVYE access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.